Science-Backed: 8,500 Steps Daily for Sustainable Weight Loss
A new analysis reveals that walking 8,500 steps per day helps sustain weight loss after diet-based programs. Researchers found participants lost nearl...
Xeber.world
obesity treatment
- electric vehicles
- automotive industry
- Stellantis
- collector cars
- automotive history
- Limited Edition
- classic cars
- Mecum Auctions
- supercar
- Formula 1
- Donald Trump
- AI ethics
- U.S. China relations
- AI adoption
- AI regulation
- artificial intelligence
- Trump administration
- inflation
- AI governance
- AI in business
- Bitcoin
- crypto regulation
- Senate Banking Committee
- CLARITY Act
- digital assets
- Digital Asset Market Clarity Act
- Federal Reserve
- Bitcoin price
- Bitcoin ETF
- crypto market
- AI cybersecurity
- cybersecurity
- CISA
- enterprise security
- CVE-2026-41089
- CVE-2026-41096
- Canvas data breach
- Instructure
- House Homeland Security Committee
- Donald Trump
- Netflix
- late-night TV
- Disney
- Paramount
- Cannes Film Festival
- Stephen Colbert
- Prime Video
- Jimmy Kimmel
- Marvel
- climate change
- renewable energy
- energy policy
- AI data centers
- geothermal energy
- Fervo Energy
- U.S. energy policy
- Strait of Hormuz
- Jason Bordoff
- Texas drought
- Subnautica 2
- Phasmophobia
- gaming news
- R.E.P.O.
- Forza Horizon 6
- FC 26
- Subnautica 2 tips
- Subnautica 2 guide
- Alan Wake event
- Destructoid
- FDA
- public health
- Marty Makary
- Trump administration
- healthcare policy
- Kyle Diamantas
- hantavirus
- health policy
- FDA leadership
- gene therapy
- Donald Trump
- Trump administration
- Supreme Court
- gerrymandering
- Iran war
- Voting Rights Act
- 2024 election
- Republican Party
- Virginia Supreme Court
- redistricting
- AI ethics
- climate change
- Elon Musk
- OpenAI
- ChatGPT
- tech industry
- Tesla
- remote sensing
- AI in the workplace
- generative AI
Hims Reports $33M Loss Amid Shift to GLP-1 Weight Loss Drugs
Hims & Hers Health Inc. (Hims) incurred a $33 million non-cash impairment charge in Q2 2024 due to its strategic pivot toward GLP-1 weight loss medica...
Bariatric Surgery Declines as GLP-1 Drugs Rise: Key Trends and Implications
Bariatric surgery rates have dropped since 2022 as GLP-1 medications gain popularity for weight loss. A new Loyola University study reveals shifting t...
Study Reveals Harsh Judgment Against GLP-1 Weight Loss Users Despite Effectiveness
A new Rice University study finds that people who lose weight using GLP-1 medications like Ozempic face greater judgment than those who regain weight...
Medicare to Offer $50/Month Weight Loss Drugs Starting July 2026: Key Facts for Beneficiaries
Medicare will launch a pilot program in July 2026 offering GLP-1 weight loss drugs like Wegovy and Zepbound for $50 per month. The initiative, running...
Survodutide Shows 16.6% Weight Loss in Phase 3 Trial, Could Rival Zepbound for Obesity and Liver Disease Treatment
Survodutide, a next-generation GLP-1 drug, achieved a 16.6% reduction in body weight in a Phase 3 trial, outperforming placebo by over 13%. The dual-a...
New AI-Powered Tool Predicts Obesity-Related Complications Beyond BMI
A groundbreaking AI model developed by researchers at Queen Mary University of London aims to predict 18 serious obesity-related complications by anal...
Study Reveals Mounjaro Causes More Lean Body Mass Loss Than Ozempic—Here’s Why It Matters
A new study suggests tirzepatide medications like Mounjaro may lead to greater lean body mass loss compared to semaglutide drugs like Ozempic. Researc...
BioAge’s Experimental Pill BGE-102 Cuts Heart-Related Inflammation by 85% in Early Study
BioAge Labs announced that its investigational cardiovascular pill, BGE-102, reduced inflammation by 85% in a Phase 1 study of obese patients. The red...
Type 2 Diabetes Risk in Young Adults: How GLP-1 Medications Can Help Prevent Progression
A new study reveals that type 2 diabetes risk among young adults with prediabetes varies widely, with those having high fasting glucose or qualifying...
FDA Approves Foundayo: New Once-Daily GLP-1 Pill for Weight Loss with Fast-Track Approval
The FDA has granted fast-track approval to Foundayo, a once-daily GLP-1 pill for weight loss developed by Eli Lilly. The medication, designed for adul...